secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001104659-25-081924
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix amends at-the-market offering agreement to reflect new S-3 registration
--------------------------------------------------------------------------------

- On August 22, 2025, amended Sales Agreement with H.C. Wainwright & Co., LLC.
- Amendment updates the registration statement to Form S-3 (No. 333-286802).
- At-the-market equity offering program terms remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925081924/0001104659-25-081924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925081924/tm2524070d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-081924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer